Esperion Therapeutis.Inc. sell platon
Summary
This prediction ended on 07.12.24 with a price of €3.39. The SELL prediction by platon shows the price for Esperion Therapeutis.Inc. slightly increased by 3.35% during the runtime of the prediction. This prediction was marked as speculative and is excluded from platon's performance statistics.Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 57.693% | 57.693% | 248.867% |
| iShares Core DAX® | 0.423% | 5.706% | 4.696% |
| iShares Nasdaq 100 | 4.096% | 16.639% | 38.946% |
| iShares Nikkei 225® | 4.469% | 18.343% | 50.386% |
| iShares S&P 500 | 1.788% | 9.644% | 26.896% |
Comments by platon for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.

